Evaluation of Serum Endocan and Testosterone Levels in Male Patients with Prediabetes: A Cross-Sectional Clinical Study

Basit Öğe Kaydı
dc.contributor.authorYigit, Onur Selcuk
dc.contributor.authorUzanulu, Mehmet Fatih
dc.contributor.authorGenc, Selin
dc.contributor.authorSahin, Ibrahim
dc.date.accessioned2026-04-04T13:31:02Z
dc.date.available2026-04-04T13:31:02Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground/Objectives: This study aimed to investigate the relationship between serum endocan and total testosterone levels in male patients with prediabetes. Materials and Methods: This cross-sectional observational study included 37 men with prediabetes and 37 healthy male controls. In addition to routine laboratory tests, blood samples were collected to measure serum endocan levels using the enzyme-linked immunosorbent assay (ELISA), and total testosterone levels were analyzed using a chemiluminescence method. Results: Age did not differ significantly between the groups (p > 0.05). Body mass index (BMI), fasting plasma glucose (FPG), postprandial plasma glucose (PPG), insulin, HbA1c, and serum endocan levels were significantly higher in the prediabetes group (BMI: p = 0.003; FPG: p < 0.001; PPG: p = 0.019; insulin: p = 0.007; HbA1c: p < 0.001; endocan: p = 0.012). No significant difference was observed in testosterone levels between the groups (p = 0.228). Conclusions: Elevated serum endocan levels in individuals with prediabetes may reflect early endothelial dysfunction associated with glycemic dysregulation. These findings suggest that endocan may serve as an exploratory biomarker of early vascular alterations in prediabetes. However, further large-scale and prospective studies are warranted to clarify its clinical relevance and potential role in risk stratification and the prediction of microvascular complications.
dc.description.sponsorshipInonu University [TTU-2022-2876]
dc.description.sponsorshipThis research was supported by the Scientific Research Projects Coordination Unit of Inonu University (Project No: TTU-2022-2876).
dc.identifier.doi10.3390/jcm15041597
dc.identifier.issn2077-0383
dc.identifier.issue4
dc.identifier.pmid41753283
dc.identifier.scopus2-s2.0-105031115539
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/jcm15041597
dc.identifier.urihttps://hdl.handle.net/11616/108539
dc.identifier.volume15
dc.identifier.wosWOS:001701239000001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectendocan
dc.subjecttestosterone
dc.subjectprediabetes
dc.subjectinsulin resistance
dc.subjectendothelial dysfunction
dc.subjecttype 2 diabetes mellitus
dc.titleEvaluation of Serum Endocan and Testosterone Levels in Male Patients with Prediabetes: A Cross-Sectional Clinical Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu